Treatment of thyroid cancer is typically total thyroidectomy, although there have been efforts to de-escelate to hemithyroidectomy in select cases. After thyroidectomy, serum thyroglobulin (Tg) is a useful tumor marker for the presence of residual disease. The American Thyroid Association recommends imaging of neck and chest for postoperative Tg >10 ng/mL (measured 6-12 weeks after surgery). FDG PET can also be considered for such patients.
In addition to following the serum Tg, the patient's risk of recurrence should be assessed. The ATA recently released their 2025 guidelines for management of differentiated thyroid cancer. The 4 risk categories and lifetime risk of recurrence are shown. This is a significant update from the 2015 guidelines which had only 3 risk categories. Risk of recurrence is driven by T staging, followed by any additional features noted in the surgical pathology report.
https://pubmed.ncbi.nlm.nih.gov/40844370/
Ringel MD, Sosa JA, Baloch Z, Bischoff L, Bloom G, Brent GA, Brock PL, Chou R, Flavell RR, Goldner W, Grubbs EG, Haymart M, Larson SM, Leung AM, Osborne J, Ridge JA, Robinson B, Steward DL, Tufano RP, Wirth LJ. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid. 2025 Aug;35(8):841-985. doi: 10.1177/10507256251363120. PMID: 40844370.